Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Jon C. Ogg | Jun 8, 2015 at 4:48 PM EDT

Is the Teva and Mylan Merger Fight Going to Turn Away Shareholders?

ThinkstockTeva Pharmaceutical Industries Ltd. (NYSE: TEVA) is trying to transform itself by making its generics business even larger if it…

Chris Lange | Jun 8, 2015 at 1:00 PM EDT

Autoimmune Drugs to Drive Big Pharma Higher in Coming Years

Credit Suisse has updated its autoimmune market model and it sees implications for all of the large cap U.S. pharmaceutical…

Jon C. Ogg | Jun 8, 2015 at 12:15 PM EDT

Events and Presentations Shake Out MannKind Short Sellers

After finally getting FDA clearance for the inhalable insulin Afrezza, and after a very slow start to the diabetes market,…

Jon C. Ogg | Jun 7, 2015 at 9:40 AM EDT

New Mega-Blockbuster Cholesterol Drug Class Faces Make-or-Break FDA Panels

This coming week is likely to be a serious one in the fight against cholesterol. FDA panels are evaluating more…

Chris Lange | Jun 7, 2015 at 9:10 AM EDT

How 6 ASCO Biotech Winners Are Focusing on the Future of Cancer

24/7 Wall St. has taken a look at some of the major ASCO winners over the past week and how…

Chris Lange | Jun 4, 2015 at 4:20 PM EDT

Tivozanib Is the Gift That Keeps on Giving for Aveo

ThinkstockAveo Pharmaceuticals Inc. (NASDAQ: AVEO) has been on a roller coaster for the past few months. Previously Aveo made a…

Chris Lange | Jun 4, 2015 at 3:36 PM EDT

Has Rite Aid’s Turnaround Already Peaked?

Some companies like to keep their investors updated on a month-to-month basis, tracking their sales. News from this can go…

Chris Lange | Jun 4, 2015 at 10:05 AM EDT

Why Opko’s Acquisition Will Transform Its Future Growth

Bio-Reference Laboratories and Opko Health announced Thursday morning that they have a definitive merger agreement in which the latter will…

Thomas Frohlich | Jun 3, 2015 at 1:34 PM EDT

Can Google Make Fast Food Healthier?

When cooking at home, measuring the health value of a meal involves reading nutritional information printed on food packages or…

Chris Lange | Jun 3, 2015 at 1:00 PM EDT

Did BioLife Solutions Run Too Much?

BioLife Solutions has been riding high on the biotech wave. However, the question is whether BioLife risen too much.

Chris Lange | Jun 3, 2015 at 10:30 AM EDT

How Halozyme Will Continue to Grow With Its New Deal

Halozyme Therapeutics has announced a global collaboration and license agreement with AbbVie.

Chris Lange | Jun 2, 2015 at 8:50 AM EDT

The 4 Overlooked Winners of ASCO

ThinkstockThe American Society of Clinical Oncology’s (ASCO) annual meeting is coming to a close. Companies and cancer drug developers across…

Chris Lange | Jun 1, 2015 at 10:50 AM EDT

Can Celladon Turn Itself Around With Its New Plan?

Celladon has announced that its board of directors unanimously approved a strategic plan to pursue either an acquisition or a…

Chris Lange | Jun 1, 2015 at 9:40 AM EDT

6 Key Cancer Winners From ASCO Presentations

24/7 Wall St. has taken a look at a few of the major ASCO winners so far. Color and background…

Lee Jackson | Jun 1, 2015 at 8:20 AM EDT

3 Specialty Pharma Stocks That Could Be Acquired in 2015

If there ever was a perfect storm for large pharmaceutical and big-cap biotech companies to make acquisitions to enhance growth…

1 … 260 261 262 263 264 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Is the Teva and Mylan Merger Fight Going to Turn Away Shareholders?

Autoimmune Drugs to Drive Big Pharma Higher in Coming Years

Events and Presentations Shake Out MannKind Short Sellers

New Mega-Blockbuster Cholesterol Drug Class Faces Make-or-Break FDA Panels

How 6 ASCO Biotech Winners Are Focusing on the Future of Cancer

Tivozanib Is the Gift That Keeps on Giving for Aveo

Has Rite Aid’s Turnaround Already Peaked?

Why Opko’s Acquisition Will Transform Its Future Growth

Can Google Make Fast Food Healthier?

Did BioLife Solutions Run Too Much?

How Halozyme Will Continue to Grow With Its New Deal

The 4 Overlooked Winners of ASCO

Can Celladon Turn Itself Around With Its New Plan?

6 Key Cancer Winners From ASCO Presentations

3 Specialty Pharma Stocks That Could Be Acquired in 2015

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Eli Lilly Captures 60% of the GLP-1 Market as Mounjaro Revenue Soars 125%

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Health and Healthcare Articles

All Health and Healthcare Articles

Is the Teva and Mylan Merger Fight Going to Turn Away Shareholders?

Autoimmune Drugs to Drive Big Pharma Higher in Coming Years

Events and Presentations Shake Out MannKind Short Sellers

New Mega-Blockbuster Cholesterol Drug Class Faces Make-or-Break FDA Panels

How 6 ASCO Biotech Winners Are Focusing on the Future of Cancer

Tivozanib Is the Gift That Keeps on Giving for Aveo

Has Rite Aid’s Turnaround Already Peaked?

Why Opko’s Acquisition Will Transform Its Future Growth

Can Google Make Fast Food Healthier?

Did BioLife Solutions Run Too Much?

How Halozyme Will Continue to Grow With Its New Deal

The 4 Overlooked Winners of ASCO

Can Celladon Turn Itself Around With Its New Plan?

6 Key Cancer Winners From ASCO Presentations

3 Specialty Pharma Stocks That Could Be Acquired in 2015

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Eli Lilly Captures 60% of the GLP-1 Market as Mounjaro Revenue Soars 125%

Featured Reads

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how